-
What Is Tumor Mutational Burden?
The Food and Drug Administration approved an immunotherapy drug for tumors with high tumor mutational burden regardless of tumor type. But some medical oncologists say it's not clear the biomarker is valid across all cancer types.
by Anna Azvolinsky
-
Taking Drug Dosing Off Autopilot
Patient advocates with metastatic breast cancer argue that dosing of treatments for their disease should be more personalized and take into account quality of life.
by Marcus A. Banks
-
Forward Look
Creating More Inclusive Clinical TrialsThe Clinical Treatment Act aims to include more Medicaid recipients.
by Jen Tota McGivney
-
Healthy Habits
Ripe for the PickingAwareness of the link between cancer risk and a diet lacking fruits and vegetables has been declining.
by Carisa D. Brewster
-
Forward Look
Cancer Screening for the LGBTQ CommunityFear of discrimination may lead to lower screening rates.
by Tara Santora
-
Forward Look
What’s Next? Fall 2020A therapeutic vaccine targeting advanced cervical cancer.
by Anna Azvolinsky
-
Worth the Wait
Neoadjuvant therapy—using treatments such as chemotherapy, hormone therapy or radiation to shrink a tumor or treat unseen metastases before surgery—can improve outcomes for some patients.
by Sharon Tregaskis
-
Facts and Stats
A Brief History of Checkpoint InhibitorsThe advent of checkpoint inhibitors has broadened the range of cancer patients able to take advantage of immunotherapy.
by Bradley Jones
-
From the Editor-in-Chief
Cancer in Minority PopulationsPaying attention to the social determinants of health will promote greater equity in cancer outcomes for all.
by William G. Nelson, MD, PhD
-
More Choices to Treat Lung Cancer
Advances in precision medicine and immunotherapy have led to better treatments for many patients with advanced lung cancer. But having a wider selection of therapies to choose from can make treatments more complex.
by Kendall K. Morgan
Cancer Talk
Understanding How High and Low Testosterone Levels Can Treat Prostate Cancer
Using high-dose testosterone after prostate cancer stops responding to androgen deprivation therapy can stop tumor growth.
by Sandra Gordon
Financial Screenings for People with CancerCancer patients say they want to be asked about their financial needs on a regular basis.
by Pamela Appea
Let Me Tell You a Story About the Power of Medical ResearchTen-year-old Michael Methner told his story about being diagnosed with optic nerve glioma at the AACR’s Rally for Medical Research.
by Cancer Research Catalyst
Aggressive Approach to Very Advanced Cancer Does Not Extend SurvivalStudy shows no benefit from treatment for cancers at very advanced stages of progression. Researchers urge end-of-life planning for these patients.
by Kyle Bagenstose